Submission of Annual Secretarial Compliance Report for the year ended 31st March. 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The company's secretarial auditor, Vishakha Agrawal & Associates, has certified that Welcure Drugs & Pharmaceuticals maintained compliance with applicable SEBI regulations during FY2025-26. The report notes three past non-compliance issues from previous periods: late submission of voting results by 9.31 minutes (Rs 11,800 fine paid), non-constitution of Audit Committee (Rs 2,14,760 fine paid, waiver applied), and non-constitution of Nomination and Remuneration Committee (Rs 2,14,760 fine paid, waiver applied). All fines have been paid in full. The statutory auditor resigned on 21st August 2025, which was within the prescribed 45-day window. Current compliance status shows full compliance across 13 check areas including secretarial standards, policies, website disclosures, director qualifications, insider trading norms, and related party transactions.
The filing shows the company has addressed past compliance lapses and is now fully compliant with SEBI regulations. Fines totaling approximately Rs 4.41 lakh have been paid. Shareholders can view this as a positive signal that governance practices have been strengthened, though the past delays in committee constitution and reporting may still warrant monitoring.